As questions continue surrounding the coverage of popular glucagon-like peptide-1 (GLP-1) drugs, benefit providers are faced with managing costs while considering the overall health of their plan participants
Petersen N, Reimann F, Bartfeld S, Farin HF, Ringnalda FC, Vries RGJ, et al
Most of the data come from animal studies or small, open label reports
Combination protocols are typically personalized based on lab work, symptoms, and overall health goals
Glutathione tackles this at a biological level by: Inhibiting tyrosinase activity to slow down melanin production Shifting melanogenesis from eumelanin (darker) to pheomelanin (lighter) Acting as an antioxidant to reduce the oxidative stress that triggers hyperpigmentation A 2025 systematic review in the International Journal of Dermatology confirms that oral glutathione at doses of 250 mg twice daily and 500 mg once daily showed a significant reduction in melanin index compared to placebo, particularly in sun-exposed areas like the face and wrists